

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Liao et al.

Application No. 10/502,040

Filed: July 19, 2004

FILED VIA EFS ON October 25, 2007

Confirmation No. 7115

For: ALANINE 2, 3-AMINOMUTASE

Examiner: Elizabeth Slobodyansky

Art Unit: 1652

Attorney Reference No. 6682-63358-09

SUBMITTED VIA ELECTRONIC FILING SYSTEM
UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT PURSUANT TO
37 C.F.R. § 1.97(d)

Listed on the accompanying form PTO-1449 and enclosed herewith are two English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent. This Information Disclosure Statement (“IDS”) is being filed after a notice of allowance and before payment of the issue fee.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicants will provide copies of such patents or applications upon request.

This statement is provided in compliance with 37 C.F.R. § 1.97(e)(1). The undersigned

hereby certifies that each item of information contained in the IDS filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the IDS.

Submitted herewith is a check for \$180.00 to cover the fee as required by 37 C.F.R. § 1.97(d) and as set forth in 37 C.F.R. § 1.17(p).


Please charge any additional fees which may be required in connection with filing this IDS, or credit any overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this sheet is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By



Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

cc: Docketing